Bruce Jackson, an analyst from Benchmark Co., has initiated a new Buy rating on Abbott Laboratories (ABT).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bruce Jackson has given his Buy rating due to a combination of factors that highlight Abbott Laboratories as a strong investment opportunity. The company’s diversified business model, which spans various healthcare sectors and geographies, provides a stable foundation for growth. This diversification helps Abbott mitigate risks associated with economic and geopolitical uncertainties, ensuring sustainable sales growth and robust earnings.
Abbott’s Diabetes Care segment, particularly the Freestyle Libre continuous glucose monitoring systems, is a significant growth driver, complemented by its Cardiovascular businesses. The company’s strategic investments in U.S. facilities position it well against potential tariff challenges, while its strong cash flow supports ongoing R&D, acquisitions, and shareholder returns. Additionally, Abbott’s nutritionals and diagnostics segments are poised for growth, further enhancing its market position and justifying the Buy rating.
In another report released on October 8, UBS also reiterated a Buy rating on the stock with a $154.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABT in relation to earlier this year.